Chapter 2

ASS234: A New and Promising Anti-Alzheimer Agent

Alejandro Romero, Eva Ramos, Ana P. Fernandez, Julia Serrano, Ricardo Martínez-Murillo and Jose Marco-Contelles

Abstract

Physiopathological events associated with the development and progression of Alzheimer's disease (AD) are complex and require new therapeutical approaches. Consequently, N-((5-(3-(1-benzylpiperidin-4-yl) propoxy)-1- methyl-1H-indol-2-yl) methyl)-N-methylprop-2-yn-1-amine (ASS234), synthesized as a new multitargetdirected molecule, has focused a great interest in this field. In vitro, it is able to cross the blood-brain barrier and has less toxicity than donepezil. It acts simultaneously as a reversible inhibitor of both human acetyl and butyrylcholinesterase, and as an irreversible inhibitor of human monoamine oxidase A and B. It inhibits both Αß1-42 and Αß1-40 self-aggregation and possesses antioxidant and neuroprotective properties. Recently, it was demonstrated that ASS234 is able to induce the wingless-type MMTV integration site family (Wnt) signaling pathway, which is involved in neuroprotective activities related to AD and it also promotes the induction of several key antioxidant genes that counteract oxidative stress. In vivo experiments, ASS234 exhibited a reduction of amyloid plaque burden and gliosis in the cortex and hippocampus and significantly decreased scopolamine-induced learning deficits in C57BL/6J mice. Herein, we summarize the neuroprotective effects of ASS234 in counteracting several steps in the pathological processes of AD.

Total Pages: 12-25 (14)

Purchase Chapter  Book Details

RELATED BOOKS

.Frontiers in Clinical Drug Research - CNS and Neurological Disorders.
.Frontiers in Clinical Drug Research-Dementia.
.Alzheimer
.Advances in Alzheimer Research.
.Recent Advances in the Treatment of Neurodegenerative Disorders.
.Alzheimer
.Advances in Alzheimer Research.
.Cellular and Molecular Biology of Autism Spectrum Disorders.